GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $2.78 billion. The enterprise value is $2.74 billion.
| Market Cap | 2.78B |
| Enterprise Value | 2.74B |
Important Dates
The next confirmed earnings date is Monday, February 23, 2026, before market open.
| Earnings Date | Feb 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 28.90 million shares outstanding. The number of shares has increased by 7.19% in one year.
| Current Share Class | 28.90M |
| Shares Outstanding | 28.90M |
| Shares Change (YoY) | +7.19% |
| Shares Change (QoQ) | -3.21% |
| Owned by Insiders (%) | 1.38% |
| Owned by Institutions (%) | 88.45% |
| Float | 20.71M |
Valuation Ratios
The trailing PE ratio is 1,335.74 and the forward PE ratio is 219.47.
| PE Ratio | 1,335.74 |
| Forward PE | 219.47 |
| PS Ratio | 6.78 |
| Forward PS | 5.47 |
| PB Ratio | 9.52 |
| P/TBV Ratio | 26.03 |
| P/FCF Ratio | 179.90 |
| P/OCF Ratio | 83.84 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 79.06, with an EV/FCF ratio of 177.19.
| EV / Earnings | 1,315.62 |
| EV / Sales | 6.81 |
| EV / EBITDA | 79.06 |
| EV / EBIT | 234.99 |
| EV / FCF | 177.19 |
Financial Position
The company has a current ratio of 2.71, with a Debt / Equity ratio of 0.39.
| Current Ratio | 2.71 |
| Quick Ratio | 2.47 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 2.72 |
| Debt / FCF | 7.32 |
| Interest Coverage | 4.29 |
Financial Efficiency
Return on equity (ROE) is 0.84% and return on invested capital (ROIC) is 3.82%.
| Return on Equity (ROE) | 0.84% |
| Return on Assets (ROA) | 1.61% |
| Return on Invested Capital (ROIC) | 3.82% |
| Return on Capital Employed (ROCE) | 2.87% |
| Weighted Average Cost of Capital (WACC) | 15.11% |
| Revenue Per Employee | $402,190 |
| Profits Per Employee | $2,083 |
| Employee Count | 1,000 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 11.44 |
Taxes
In the past 12 months, GeneDx Holdings has paid $424,000 in taxes.
| Income Tax | 424,000 |
| Effective Tax Rate | 16.91% |
Stock Price Statistics
The stock price has increased by +27.21% in the last 52 weeks. The beta is 2.07, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.07 |
| 52-Week Price Change | +27.21% |
| 50-Day Moving Average | 133.71 |
| 200-Day Moving Average | 109.95 |
| Relative Strength Index (RSI) | 29.62 |
| Average Volume (20 Days) | 722,823 |
Short Selling Information
The latest short interest is 3.62 million, so 12.52% of the outstanding shares have been sold short.
| Short Interest | 3.62M |
| Short Previous Month | 3.07M |
| Short % of Shares Out | 12.52% |
| Short % of Float | 17.48% |
| Short Ratio (days to cover) | 6.68 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $402.19 million and earned $2.08 million in profits. Earnings per share was $0.07.
| Revenue | 402.19M |
| Gross Profit | 280.11M |
| Operating Income | 11.66M |
| Pretax Income | 2.51M |
| Net Income | 2.08M |
| EBITDA | 34.66M |
| EBIT | 11.66M |
| Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $155.08 million in cash and $113.16 million in debt, with a net cash position of $41.92 million or $1.45 per share.
| Cash & Cash Equivalents | 155.08M |
| Total Debt | 113.16M |
| Net Cash | 41.92M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 292.26M |
| Book Value Per Share | 10.12 |
| Working Capital | 149.96M |
Cash Flow
In the last 12 months, operating cash flow was $33.19 million and capital expenditures -$17.72 million, giving a free cash flow of $15.47 million.
| Operating Cash Flow | 33.19M |
| Capital Expenditures | -17.72M |
| Free Cash Flow | 15.47M |
| FCF Per Share | $0.54 |
Margins
Gross margin is 69.65%, with operating and profit margins of 2.90% and 0.52%.
| Gross Margin | 69.65% |
| Operating Margin | 2.90% |
| Pretax Margin | 0.62% |
| Profit Margin | 0.52% |
| EBITDA Margin | 8.62% |
| EBIT Margin | 2.90% |
| FCF Margin | 3.85% |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.19% |
| Shareholder Yield | -7.19% |
| Earnings Yield | 0.07% |
| FCF Yield | 0.56% |
Analyst Forecast
The average price target for GeneDx Holdings is $138.13, which is 43.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $138.13 |
| Price Target Difference | 43.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 24.65% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 4.62 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.62 |
| Piotroski F-Score | 8 |